PL EN


Preferences help
enabled [disable] Abstract
Number of results
1997 | 51 | 2 | 227-236
Article title

L-MTO-PE - a potential drug for cancer therapy

Title variants
Languages of publication
PL
Abstracts
EN
Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a syntetic lipophilic analogue of muramyl dipeptide, stimulates monocytes/macrophages to kill a variety of tumor cells in vitro and in vivo. Encapsulation of MTP-PE into multilamellar liposomes (L-MTP-PE) was specifically designed for in vivo targeting to macrophages by i.v. infusion and is the only form of the drug currently available for clinical trials (CGP 19835A Lipid). L-MTP-PE is presently undergoing clinical trials in patients with recurrent osteosarcoma and melanoma. L-MTP-PE combined with other anticancer agents may thus improve long-term cure rates of patients with this diseases.
Keywords
Year
Volume
51
Issue
2
Pages
227-236
Physical description
Contributors
References
Document Type
article
Publication order reference
K.Dzierzbicka, ul. Przyjemna 2c/11, 80-054 Gdansk, Poland
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-baff14da-b5a8-3f7f-8e0d-bfb0fa644aa3
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.